Your browser is no longer supported. Please, upgrade your browser.
Settings
ARNA Arena Pharmaceuticals, Inc. daily Stock Chart
ARNA [NASD]
Arena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.38 Insider Own0.59% Shs Outstand243.29M Perf Week-1.34%
Market Cap357.64M Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float242.12M Perf Month1.38%
Income-91.50M PEG- EPS next Q-0.08 Inst Own47.40% Short Float3.78% Perf Quarter-2.65%
Sales46.40M P/S7.71 EPS this Y-62.90% Inst Trans-6.16% Short Ratio5.63 Perf Half Y-7.55%
Book/sh0.01 P/B147.00 EPS next Y-3.00% ROA-39.50% Target Price4.50 Perf Year-2.00%
Cash/sh0.42 P/C3.52 EPS next 5Y- ROE-339.10% 52W Range1.34 - 2.16 Perf YTD3.52%
Dividend- P/FCF- EPS past 5Y17.00% ROI-84.70% 52W High-31.94% Beta-0.70
Dividend %- Quick Ratio2.10 Sales past 5Y18.20% Gross Margin73.50% 52W Low9.55% ATR0.07
Employees228 Current Ratio2.20 Sales Q/Q111.00% Oper. Margin- RSI (14)48.13 Volatility4.45% 4.83%
OptionableYes Debt/Eq20.03 EPS Q/Q53.40% Profit Margin- Rel Volume0.55 Prev Close1.42
ShortableYes LT Debt/Eq19.00 EarningsFeb 27 AMC Payout- Avg Volume1.63M Price1.47
Recom2.40 SMA20-2.20% SMA500.10% SMA200-8.75% Volume886,668 Change3.52%
Sep-15-16Initiated FBR & Co. Outperform $6
Mar-01-16Reiterated RBC Capital Mkts Sector Perform $2 → $1.50
Nov-11-15Reiterated RBC Capital Mkts Sector Perform $5 → $2
Oct-28-15Reiterated WallachBeth Buy $6 → $4
May-12-15Reiterated WallachBeth Buy $8 → $6
Jan-23-15Initiated RBC Capital Mkts Sector Perform $5
Aug-07-14Reiterated WallachBeth Buy $9 → $8
Nov-15-13Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Market Perform $4.50
Oct-25-10Reiterated Barclays Capital Underweight $3 → $2
Sep-20-10Reiterated UBS Neutral $7 → $2
Sep-17-10Downgrade Davenport Buy → Neutral
Sep-14-10Downgrade Barclays Capital Equal Weight → Underweight $4 → $3
Aug-23-10Reiterated UBS Neutral $3.50 → $7
Jul-16-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1
Jul-02-10Reiterated UBS Buy $40 → $38
Feb-04-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
Dec-17-09Initiated Jefferies & Co Hold $4
Sep-21-09Downgrade Leerink Swann Outperform → Mkt Perform $6
Sep-18-09Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $3
Feb-22-17 08:14AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : February 22, 2017
Feb-14-17 09:02AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:30AM  Arena Pharmaceuticals Appoints Three New Members to Board of Directors PR Newswire
Feb-09-17 08:30AM  Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017 PR Newswire
Jan-30-17 07:22AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 30, 2017
Jan-13-17 08:25AM  Why Arena Pharmaceuticals Stock Sank in 2016 at Motley Fool
Jan-11-17 03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-09-17 06:07PM  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
08:10AM  Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
Jan-06-17 04:48PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
10:40AM  Arena Pharmaceuticals Dumps Belviq Weight Loss Drug at Investopedia
08:43AM  Genocea Stock Up on Positive Genital Herpes Infections Data
08:32AM  Biogen Licenses Amunix's XTEN Technology for Factor IX Drug
Jan-05-17 10:37AM  Arena, Eisai Modify Marketing & Supply Agreement for Belviq
09:38AM  Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
08:16AM  Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
08:07AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : January 5, 2017
Jan-04-17 09:01PM  Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin ACN Newswire
04:23PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
04:05PM  Arena Pharmaceuticals and Eisai Amend Marketing and Supply Agreement for BELVIQ Globally PR Newswire
09:43AM  Clovis Declares Pricing of Upsized Offering of Common Stock
08:33AM  Allergan Natrelle Inspira Breast Implants Approved in the U.S.
Jan-03-17 08:53AM  Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?
Dec-27-16 10:17AM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : December 27, 2016
Dec-26-16 07:29AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : December 26, 2016
Dec-19-16 01:30PM  Eisai and Arena Pharmaceuticals Announce Regulatory Approval of BELVIQ® (lorcaserin HCl) in Brazil PR Newswire
12:58PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : December 19, 2016
Dec-18-16 02:27PM  Is Arena Pharmaceuticals, Inc. (ARNA) A Good Stock To Buy? at Insider Monkey
07:35AM  Tax-Loss Selling: 3 Stocks to Dump Right Now at Motley Fool
Dec-13-16 08:30AM  Arena Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-08-16 12:12PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : December 8, 2016
Dec-07-16 08:30AM  Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH) PR Newswire -5.41%
Dec-02-16 02:47PM  The Worst Marijuana Stocks in 2016 at Motley Fool
Nov-30-16 08:30AM  Arena Pharmaceuticals Announces Four Upcoming Presentations at the 2016 Advances in Inflammatory Bowel Diseases: Crohn's & Colitis Foundation's Clinical and Research Conference PR Newswire
Nov-28-16 06:52PM  Should You Follow Hedge Funds Into Healthways, Inc. (HWAY)? at Insider Monkey -5.30%
11:52AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 28, 2016
Nov-22-16 11:08AM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-17-16 01:04PM  ARENA PHARMACEUTICALS INC Financials
Nov-15-16 01:12PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : November 15, 2016
Nov-14-16 07:56AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : November 14, 2016
Nov-09-16 04:30PM  Arena Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference PR Newswire
04:09PM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
08:30AM  Arena Pharmaceuticals Announces Poster at the American Heart Association (AHA) Scientific Sessions 2016 PR Newswire
Nov-08-16 11:06AM  3 Things You Really Need to Know About Arena Pharmaceuticals, Inc. Q3 Results at Motley Fool
08:11AM  Arena (ARNA) Q3 Loss Lower than Expected, Revenues Rise
07:29AM  Arena Pharmaceuticals Shed Even More Weight in October at Motley Fool
Nov-07-16 06:37PM  Edited Transcript of ARNA earnings conference call or presentation 7-Nov-16 9:30pm GMT +5.76%
05:40PM  Arena Pharmaceuticals reports 3Q loss
04:37PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Arena Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q3 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Nov-04-16 05:39PM  Arena (ARNA) Q3 Earnings: Will the Stock Pull a Surprise?
Nov-03-16 08:05AM  Eisai and Arena Pharmaceuticals Announce Presentation of BELVIQ® (lorcaserin HCl) Data at 2016 Annual Obesity Week Meeting PR Newswire
Oct-31-16 04:30PM  Arena Pharmaceuticals to Release Third Quarter 2016 Financial Results and Provide Corporate Update on Monday, November 7, 2016 PR Newswire
Oct-28-16 01:33PM  Telling a Half-Truth Doesn't Work for Drugmaker at Bloomberg
Oct-18-16 09:23AM  Biotech Review DVAX Vaccine Faces Crucial PDUFA Date, CLDX Seeks Fast-Track Orphan Drug Status CNW Group
Oct-17-16 09:50AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : October 17, 2016
08:44AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : October 17, 2016
Oct-11-16 11:14AM  Why Arena Pharmaceuticals Is Finally Showing Some Signs of Life at Motley Fool
08:30AM  Arena Pharmaceuticals Announces Acceptance of Late Breaking Etrasimod Abstract at the United European Gastroenterology Week (UEGW) Meeting PR Newswire
Oct-04-16 05:41PM  New Tablet Supports Weight Loss Management (ARNA) at Investopedia
Oct-03-16 09:14PM  BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States ACN Newswire
10:21AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : October 3, 2016
09:01AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:06AM  Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets PR Newswire
Sep-19-16 03:48PM  Arena Launches Drug Discovery Incubator (ARNA) at Investopedia
11:09AM  Arena Pharmaceuticals, Inc. Value Analysis (NASDAQ:ARNA) : September 19, 2016
Sep-16-16 08:17AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : September 16, 2016
Sep-15-16 05:55AM  Coverage initiated on Arena Pharm by FBR & Co. +12.99%
Sep-12-16 10:52AM  How Hedge Funds Were Passing Around Marijuana Stocks in Q2 at Insider Monkey +5.41%
10:29AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : September 12, 2016
Sep-02-16 10:06AM  Arena (ARNA) Beacon Discovery to Boost Research Platform
Sep-01-16 05:00PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
04:30PM  Arena Pharmaceutics Announces Formation of Beacon Discovery PR Newswire
Aug-25-16 06:04AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Aug-23-16 11:20AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : August 23, 2016
Aug-17-16 09:29AM  Biotech Industry on the Upswing after Rocky Start to 2016
Aug-15-16 04:03PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
07:00AM  Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer PR Newswire
Aug-11-16 12:30PM  ETFs with exposure to Arena Pharmaceuticals, Inc. : August 11, 2016
Aug-10-16 01:28PM  Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
Aug-09-16 07:19AM  Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
06:10AM  ARENA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-08-16 05:38PM  How Will Arena Pharmaceuticals (ARNA) Stock React to Q2 Miss?
04:51PM  Arena Pharmaceuticals reports 2Q loss
04:12PM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:01PM  Arena Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
02:19PM  What to Expect in Arena Pharmaceuticals Earnings? at Investopedia
07:07AM  Q2 2016 Arena Pharmaceuticals Inc Earnings Release - After Market Close
Aug-01-16 04:01PM  Arena Pharmaceuticals to Release Second Quarter 2016 Financial Results and Provide Corporate Update on Monday, August 8, 2016 PR Newswire
08:56AM  Arena (ARNA) Q2 Earnings: What's in Store for the Stock?
Jul-26-16 11:42AM  ETFs with exposure to Arena Pharmaceuticals, Inc. : July 26, 2016
Jul-21-16 08:17AM  Arena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : July 21, 2016
Jul-20-16 10:10AM  Company News for July 20, 2016
Jul-19-16 12:43PM  Arena Pharmaceuticals (ARNA) Stock Gains as FDA Approves Weight-Loss Drug
10:20AM  Eisai And Arena Pharmaceuticals Get FDA Approval For BELVIQ XR Extended-Release Tablets
09:02AM  ARENA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
08:40AM  Arena Pharma stock rises 8.8% after weight-loss drug is approved at MarketWatch
08:26AM  Eisai Inc. and Arena Pharmaceuticals Announce FDA Approval of BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets PR Newswire
Jul-14-16 11:51AM  Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENESPRI In Mexico
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas. It focuses on three primary proprietary investigational clinical programs: etrasimod (APD334), which is in Phase 2 evaluation for ulcerative colitis, as well as initiating Phase 2 clinical trials for additional indications; APD371 that is entering in Phase 2 evaluation for the treatment of pain associated with Crohn's disease; and ralinepag (APD811), which is in Phase 2 evaluation for pulmonary arterial hypertension. The company has collaboration agreements with Eisai Co., Ltd., Eisai Inc., Axovant Sciences, and Boehringer Ingelheim International GmbH. The company was founded in 1997 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
White Christine AnnaDirectorJun 13Sale1.9918,72837,29985,529Jun 15 08:55 PM